Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) have been assigned an average rating of “Moderate Buy” from the fifteen research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and twelve have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $19.3636.

Several research analysts have issued reports on ORIC shares. Citigroup cut their price target on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Oric Pharmaceuticals in a report on Thursday, April 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Tuesday, April 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a report on Friday, May 22nd. Finally, Oppenheimer restated an “outperform” rating and issued a $15.00 target price on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Oric Pharmaceuticals by 105.5% in the first quarter. Bank of America Corp DE now owns 1,043,159 shares of the company’s stock valued at $13,217,000 after purchasing an additional 535,649 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Oric Pharmaceuticals by 42.4% in the first quarter. California State Teachers Retirement System now owns 48,369 shares of the company’s stock valued at $613,000 after purchasing an additional 14,410 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Oric Pharmaceuticals by 41.6% in the first quarter. The Manufacturers Life Insurance Company now owns 182,139 shares of the company’s stock valued at $2,308,000 after purchasing an additional 53,490 shares in the last quarter. Quantinno Capital Management LP lifted its holdings in shares of Oric Pharmaceuticals by 9.3% in the first quarter. Quantinno Capital Management LP now owns 25,526 shares of the company’s stock valued at $323,000 after purchasing an additional 2,170 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new position in shares of Oric Pharmaceuticals in the first quarter valued at approximately $538,000. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Price Performance

Shares of ORIC opened at $7.62 on Wednesday. The stock has a 50-day moving average of $9.66 and a 200-day moving average of $10.42. The company has a market cap of $788.82 million, a PE ratio of -5.29 and a beta of 1.04. Oric Pharmaceuticals has a one year low of $7.23 and a one year high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Analysts expect that Oric Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.